This announcement is a separate document:
华东医药：监事会关于调整2022年限制性股票激励计划回购价格及回购注销部分限制性股票的核查意见（更新后）
Huadong Medicine: The supervisory board's verification opinion on the adjustment of the 2022 restricted stock incentive plan repurchase price and repurchase cancellation of some restricted stocks (updated).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated